Clinical Laboratory Improvement Advisory Committee, 13121-13122 [2017-04621]
Download as PDF
Federal Register / Vol. 82, No. 45 / Thursday, March 9, 2017 / Notices
Status: The meeting will be closed to
the public in accordance with
provisions set forth in Section 552b(c)
(4) and (6), Title 5 U.S.C., and the
Determination of the Director,
Management Analysis and Services
Office, CDC, pursuant to Public Law 92–
463.
Matters for Discussion: The meeting
will include the initial review,
discussion, and evaluation of
applications received in response to
‘‘Validation of Survey Questions to
Distinguish Type 1 and Type 2 Diabetes
among Adults with Diabetes’’, FOA
DP17–002.
Contact Person for More Information:
Jaya Raman Ph.D., Scientific Review
Officer, CDC, 4770 Buford Highway,
Mailstop F80, Atlanta, Georgia 30341,
Telephone: (770) 488–6511, kva5@
cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2017–04623 Filed 3–8–17; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
asabaliauskas on DSK3SPTVN1PROD with NOTICES
Clinical Laboratory Improvement
Advisory Committee
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following committee
meeting.
Times and Dates:
8:30 a.m.–5:00 p.m., EDT, April 12,
2017
8:30 a.m.–12:00 p.m., EDT, April 13,
2017
Place: CDC, 1600 Clifton Road NE.,
Tom Harkin Global Communications
Center, Building 19, Auditorium B,
Atlanta, Georgia 30333.
Status: Open to the public, limited
only by the space available. The meeting
room accommodates approximately 100
people. This meeting will also be
webcast, please see information below.
VerDate Sep<11>2014
17:43 Mar 08, 2017
Jkt 241001
Purpose: This Committee is charged
with providing scientific and technical
advice and guidance to the Secretary of
Health and Human Services (HHS); the
Assistant Secretary for Health; the
Director, Centers for Disease Control
and Prevention; the Commissioner,
Food and Drug Administration (FDA);
and the Administrator, Centers for
Medicare and Medicaid Services (CMS).
The advice and guidance pertain to
general issues related to improvement in
clinical laboratory quality and
laboratory medicine practice and
specific questions related to possible
revision of the Clinical Laboratory
Improvement Amendment (CLIA)
standards. Examples include providing
guidance on studies designed to
improve safety, effectiveness, efficiency,
timeliness, equity, and patientcenteredness of laboratory services;
revisions to the standards under which
clinical laboratories are regulated; the
impact of proposed revisions to the
standards on medical and laboratory
practice; and the modification of the
standards and provision of nonregulatory guidelines to accommodate
technological advances, such as new
test methods, the electronic
transmission of laboratory information,
and mechanisms to improve the
integration of public health and clinical
laboratory practices.
Matters for Discussion: The agenda
will include agency updates from CDC,
CMS, and FDA. Presentations and
discussions will focus on the
implementation of next generation
sequencing in clinical laboratories;
laboratory testing in the era of
telemedicine; and a report from the
Institute of Medicine (IOM) CLIAC
workgroup.
Agenda items are subject to change as
priorities dictate.
Webcast: The meeting will also be
webcast. Persons interested in viewing
the webcast can access information at:
https://
cdclabtraining.adobeconnect.com/
aprilcliac/.
Online Registration Required: All
people attending the CLIAC meeting inperson are required to register for the
meeting online at least 5 business days
in advance for U.S. citizens and at least
10 business days in advance for
international registrants. Register at:
https://wwwn.cdc.gov/cliac/Meetings/
MeetingDetails.aspx. Register by
scrolling down and clicking the
‘‘Register for this Meeting’’ button and
completing all forms according to the
instructions given. Please complete all
the required fields before submitting
your registration and submit no later
than April 5, 2017 for U.S. registrants
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
13121
and March 29, 2017 for international
registrants.
Providing Oral or Written Comments:
It is the policy of CLIAC to accept
written public comments and provide a
brief period for oral public comments on
agenda items. Public comment periods
for each agenda item are scheduled
immediately prior to the Committee
discussion period for that item.
Oral Comments: In general, each
individual or group requesting to make
oral comments will be limited to a total
time of five minutes (unless otherwise
indicated). Speakers must also submit
their comments in writing for inclusion
in the meeting’s Summary Report. To
assure adequate time is scheduled for
public comments, speakers should
notify the contact person below at least
one week prior to the meeting date.
Written Comments: For individuals or
groups unable to attend the meeting,
CLIAC accepts written comments until
the date of the meeting (unless
otherwise stated). However, it is
requested that comments be submitted
at least one week prior to the meeting
date so that the comments may be made
available to the Committee for their
consideration and public distribution.
Written comments, one hard copy with
original signature, should be provided
to the contact person at the mailing or
email address below, and will be
included in the meeting’s Summary
Report.
Availability of Meeting Materials: To
support the green initiatives of the
federal government, the CLIAC meeting
materials will be made available to the
Committee and the public in electronic
format (PDF) on the internet instead of
by printed copy. Check the CLIAC Web
site on the day of the meeting for
materials: https://wwwn.cdc.gov/cliac/
Meetings/MeetingDetails.aspx. Note: If
using a mobile device to access the
materials, please verify that the device’s
browser is able to download the files
from the CDC’s Web site before the
meeting.
Alternatively, the files can be
downloaded to a computer and then
emailed to the portable device. An
internet connection, power source, and
limited hard copies may be available at
the meeting location, but cannot be
guaranteed.
Contact Person for Additional
Information: Nancy Anderson, Chief,
Laboratory Practice Standards Branch,
Division of Laboratory Systems, Center
for Surveillance, Epidemiology and
Laboratory Services, Office of Public
Health Scientific Services, CDC, 1600
Clifton Road NE., Mailstop F–11,
Atlanta, Georgia 30329–4018; telephone
E:\FR\FM\09MRN1.SGM
09MRN1
13122
Federal Register / Vol. 82, No. 45 / Thursday, March 9, 2017 / Notices
(404) 498–2741; or via email at
NAnderson@cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
Notices pertaining to announcements of
meetings and other committee
management activities, for the Centers
for Disease Control and Prevention and
the Agency for Toxic Substances and
Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2017–04621 Filed 3–8–17; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
asabaliauskas on DSK3SPTVN1PROD with NOTICES
Board of Scientific Counselors,
National Institute for Occupational
Safety and Health (BSC, NIOSH)
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following meeting for the
aforementioned committee:
Time and Date: 8:30 a.m.–12:45 p.m.,
EDT, April 12, 2017.
Place: 1095 Willowdale Road,
Morgantown, WV 26505. The meeting is
also available via webcast.
Status: This meeting is open to the
public, limited only by the space
available. The meeting room
accommodates approximately 50
people. The public is welcome to
participate during the public comment
period, 9:20 a.m.–9:30 a.m. EDT, April
12, 2017. Please note that the public
comment period ends at the time
indicated above or following the last
call for comments, whichever is earlier.
Members of the public who want to
comment must sign up by providing
their name by mail, email, or telephone,
at the addresses provided below by
April 7, 2017. Each commenter will be
provided up to five minutes for
comment. A limited number of time
slots are available and will be assigned
on a first come-first served basis.
Written comments will also be accepted
from those unable to attend the public
session via an on-line form at the
following Web site: https://www.cdc.gov/
niosh/bsc/contact.html. The meeting is
also open to the public via webcast. If
you wish to attend in person or by
webcast, please see the NIOSH Web site
to register (https://www.cdc.gov/niosh/
VerDate Sep<11>2014
17:43 Mar 08, 2017
Jkt 241001
bsc/) or call (404–498–2539) at least five
business days in advance of the
meeting. Teleconference is available
toll-free; please dial (888) 397–9578,
Participant Pass Code 63257516. Adobe
Connect webcast will be available at
https://odniosh.adobeconnect.com/
nioshbsc/ for participants wanting to
connect remotely.
Purpose: The Secretary, the Assistant
Secretary for Health, and by delegation
the Director, Centers for Disease Control
and Prevention, are authorized under
Sections 301 and 308 of the Public
Health Service Act to conduct directly
or by grants or contracts, research,
experiments, and demonstrations
relating to occupational safety and
health and to mine health. The Board of
Scientific Counselors provides guidance
to the Director, National Institute for
Occupational Safety and Health on
research and prevention programs.
Specifically, the Board provides
guidance on the Institute’s research
activities related to developing and
evaluating hypotheses, systematically
documenting findings and
disseminating results. The Board
evaluates the degree to which the
activities of the National Institute for
Occupational Safety and Health: (1)
Conform to appropriate scientific
standards, (2) address current, relevant
needs, and (3) produce intended results.
Matters for Discussion: NIOSH
Director’s update; occupational motor
vehicle safety, the nanotoxicolgy
program, flu-related research, and mold
investigations.
Agenda items are subject to change as
priorities dictate.
An agenda is also posted on the
NIOSH Web site (https://www.cdc.gov/
niosh/bsc/). Members of the public who
wish to address the NIOSH BSC are
requested to contact the Executive
Secretary for scheduling purposes (see
contact information below).
Alternatively, written comments to the
BSC may be submitted via an on-line
form at the following Web site: https://
www.cdc.gov/niosh/bsc/contact.html.
Contact Person for More Information:
Paul J. Middendorf, Ph.D., Executive
Secretary, BSC, NIOSH, CDC, 1600
Clifton Road NE., MS–E20, Atlanta, GA
30329–4018, telephone (404) 498–2500,
fax (404) 498–2526.
The Director, Management Analysis
and Services Office has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention (CDC).
[FR Doc. 2017–04620 Filed 3–8–17; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket Number CDC–2017–0017, NIOSH
153–D]
Proposed Revised Definitions for the
Levels of Evidence for NIOSH Skin
Notation Profiles; Request for
Comment
National Institute for
Occupational Safety and Health
(NIOSH) of the Centers for Disease
Control and Prevention (CDC),
Department of Health and Human
Services (HHS).
ACTION: Request for comments.
AGENCY:
The National Institute for
Occupational Safety and Health
(NIOSH) of the Centers for Disease
Control and Prevention (CDC) proposes
to clarify the definitions for ‘sufficient’,
‘limited’, and ‘insufficient’ levels of
evidence for the designation of NIOSH
skin notations. In NIOSH Current
Intelligence Bulletin (CIB) 61—A
Strategy for Assigning New NIOSH Skin
Notations, Appendix E.2, Evaluation of
data, pp. 41–42 [https://www.cdc.gov/
niosh/docs/2009-147/pdfs/2009147.pdf] these levels of evidence are
defined as the following:
‘‘Data sets classified as sufficient are
those that include human and/or animal
toxicity studies conducted according to
standardized protocols and that provide
in-depth descriptions of the exposure
conditions and study findings. Data sets
classified as limited via the qualitative
ranking scheme contain either human
and/or animal studies conducted by
non-standardized protocols or contain
incomplete descriptions of the exposure
conditions and study findings. Data sets
classified as insufficient include studies
that primarily either did not apply
standard protocols or did not provide an
in-depth description of the exposure
conditions or study findings. Data sets
that receive the insufficient ranking will
not be used as the basis for the NIOSH
skin notation.’’
NIOSH proposes to clarify the
definitions for the sufficient, limited,
SUMMARY:
E:\FR\FM\09MRN1.SGM
09MRN1
Agencies
[Federal Register Volume 82, Number 45 (Thursday, March 9, 2017)]
[Notices]
[Pages 13121-13122]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-04621]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Clinical Laboratory Improvement Advisory Committee
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces the following committee meeting.
Times and Dates:
8:30 a.m.-5:00 p.m., EDT, April 12, 2017
8:30 a.m.-12:00 p.m., EDT, April 13, 2017
Place: CDC, 1600 Clifton Road NE., Tom Harkin Global Communications
Center, Building 19, Auditorium B, Atlanta, Georgia 30333.
Status: Open to the public, limited only by the space available.
The meeting room accommodates approximately 100 people. This meeting
will also be webcast, please see information below.
Purpose: This Committee is charged with providing scientific and
technical advice and guidance to the Secretary of Health and Human
Services (HHS); the Assistant Secretary for Health; the Director,
Centers for Disease Control and Prevention; the Commissioner, Food and
Drug Administration (FDA); and the Administrator, Centers for Medicare
and Medicaid Services (CMS). The advice and guidance pertain to general
issues related to improvement in clinical laboratory quality and
laboratory medicine practice and specific questions related to possible
revision of the Clinical Laboratory Improvement Amendment (CLIA)
standards. Examples include providing guidance on studies designed to
improve safety, effectiveness, efficiency, timeliness, equity, and
patient-centeredness of laboratory services; revisions to the standards
under which clinical laboratories are regulated; the impact of proposed
revisions to the standards on medical and laboratory practice; and the
modification of the standards and provision of non-regulatory
guidelines to accommodate technological advances, such as new test
methods, the electronic transmission of laboratory information, and
mechanisms to improve the integration of public health and clinical
laboratory practices.
Matters for Discussion: The agenda will include agency updates from
CDC, CMS, and FDA. Presentations and discussions will focus on the
implementation of next generation sequencing in clinical laboratories;
laboratory testing in the era of telemedicine; and a report from the
Institute of Medicine (IOM) CLIAC workgroup.
Agenda items are subject to change as priorities dictate.
Webcast: The meeting will also be webcast. Persons interested in
viewing the webcast can access information at: https://cdclabtraining.adobeconnect.com/aprilcliac/.
Online Registration Required: All people attending the CLIAC
meeting in-person are required to register for the meeting online at
least 5 business days in advance for U.S. citizens and at least 10
business days in advance for international registrants. Register at:
https://wwwn.cdc.gov/cliac/Meetings/MeetingDetails.aspx. Register by
scrolling down and clicking the ``Register for this Meeting'' button
and completing all forms according to the instructions given. Please
complete all the required fields before submitting your registration
and submit no later than April 5, 2017 for U.S. registrants and March
29, 2017 for international registrants.
Providing Oral or Written Comments: It is the policy of CLIAC to
accept written public comments and provide a brief period for oral
public comments on agenda items. Public comment periods for each agenda
item are scheduled immediately prior to the Committee discussion period
for that item.
Oral Comments: In general, each individual or group requesting to
make oral comments will be limited to a total time of five minutes
(unless otherwise indicated). Speakers must also submit their comments
in writing for inclusion in the meeting's Summary Report. To assure
adequate time is scheduled for public comments, speakers should notify
the contact person below at least one week prior to the meeting date.
Written Comments: For individuals or groups unable to attend the
meeting, CLIAC accepts written comments until the date of the meeting
(unless otherwise stated). However, it is requested that comments be
submitted at least one week prior to the meeting date so that the
comments may be made available to the Committee for their consideration
and public distribution. Written comments, one hard copy with original
signature, should be provided to the contact person at the mailing or
email address below, and will be included in the meeting's Summary
Report.
Availability of Meeting Materials: To support the green initiatives
of the federal government, the CLIAC meeting materials will be made
available to the Committee and the public in electronic format (PDF) on
the internet instead of by printed copy. Check the CLIAC Web site on
the day of the meeting for materials: https://wwwn.cdc.gov/cliac/Meetings/MeetingDetails.aspx. Note: If using a mobile device to access
the materials, please verify that the device's browser is able to
download the files from the CDC's Web site before the meeting.
Alternatively, the files can be downloaded to a computer and then
emailed to the portable device. An internet connection, power source,
and limited hard copies may be available at the meeting location, but
cannot be guaranteed.
Contact Person for Additional Information: Nancy Anderson, Chief,
Laboratory Practice Standards Branch, Division of Laboratory Systems,
Center for Surveillance, Epidemiology and Laboratory Services, Office
of Public Health Scientific Services, CDC, 1600 Clifton Road NE.,
Mailstop F-11, Atlanta, Georgia 30329-4018; telephone
[[Page 13122]]
(404) 498-2741; or via email at NAnderson@cdc.gov.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register Notices pertaining to
announcements of meetings and other committee management activities,
for the Centers for Disease Control and Prevention and the Agency for
Toxic Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2017-04621 Filed 3-8-17; 8:45 am]
BILLING CODE 4163-18-P